Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LEEEF | CLUSTER | bullish | 5/10 | CEO and CFO of Leef Brands made open-market purchases totaling ~$48K on May 18, 2026, with an additional non-cash compon | May 21, 2026 |
| MRNA | 144 | neutral | 2/10 | Flagship Pioneering, LLC, a major early investor in Moderna, filed a Form 144 to sell 9,263 shares of common stock with | May 21, 2026 |
| TVGN | PRESS-RELEASE | neutral | 4/10 | Tevogen Bio announced a non-binding Letter of Intent to evaluate a potential transaction with a Management Services Orga | May 21, 2026 |
| MTEX | CLUSTER | mixed | 5/10 | Two directors at micro-cap Mannatech (MTEX) made open-market purchases totaling $62K over three trades in a 7-day window | May 21, 2026 |
| AIM | 8-K | bearish | 8/10 | AIM ImmunoTech entered into a securities purchase agreement and placement agency agreement for a combined registered dir | May 21, 2026 |
| AIM | 424B5 | bearish | 7/10 | AIM ImmunoTech is pricing a ~$2.44M best-efforts public offering of 7,519,351 shares at $0.325/share (20.7% discount to | May 21, 2026 |
| TLSA | PRESS-RELEASE | bullish | 7/10 | Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a INFORM-MS trial of intranasal foralumab | May 21, 2026 |
| TLSA | 6-K | bullish | 6/10 | Tiziana Life Sciences announced completion of patient enrollment (n=48) in its Phase 2a placebo-controlled trial (INFORM | May 21, 2026 |
| NBTX | PRESS-RELEASE | bearish | 6/10 | Nanobiotix priced a global follow-on offering of 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warra | May 21, 2026 |
| NBTX | PRESS-RELEASE | bearish | 6/10 | Nanobiotix priced a global follow-on offering raising ~$98.6M gross ($85M equivalent) via 2,184,662 ordinary shares (inc | May 21, 2026 |
| HCWB | PRESS-RELEASE | bearish | 6/10 | HCW Biologics priced a private placement of ~2.85M units at $1.405/unit, raising ~$4M in gross proceeds. The offering in | May 21, 2026 |
| JUNS | 8-K | bearish | 6/10 | Jupiter Neurosciences priced a registered direct offering of 7,142,858 shares at $0.28/share, raising ~$2.0M gross proce | May 21, 2026 |
| AKTX | PRESS-RELEASE | bearish | 6/10 | Akari Therapeutics announced a private placement raising approximately $5.5 million through the sale of 1,470,588 ADSs a | May 21, 2026 |
| CRBP | 8-K | neutral | 4/10 | Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year employment agreement | May 21, 2026 |
| JUNS | 424B5 | bearish | 6/10 | Jupiter Neurosciences has priced a registered direct offering of 7,142,858 shares of common stock at $0.28 per share, ra | May 21, 2026 |
| CGTX | PRESS-RELEASE | bullish | 6/10 | Cognition Therapeutics held a productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER study results for zervi | May 21, 2026 |
| SVA | 6-K | neutral | 2/10 | Sinovac extended the deadline for shareholders to submit payment instructions for its previously declared $55.00 per sha | May 21, 2026 |
| COAG | PRESS-RELEASE | neutral | 5/10 | Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q | May 21, 2026 |
| HMDCF | 6-K | bullish | 7/10 | HUTCHMED and Innovent announced NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab) for seco | May 21, 2026 |
| IMMX | PRESS-RELEASE | bullish | 8/10 | Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have conv | May 21, 2026 |
| NBTX | PRESS-RELEASE | bearish | 6/10 | Nanobiotix has temporarily halted trading on Euronext Paris to finalize allocations and announce pricing for its previou | May 21, 2026 |
| LQDA | CLUSTER | mixed | 5/10 | LQDA CEO Roger Jeffs sold $5.84M worth of stock over four consecutive trading days (May 15-20) at prices between $56.77 | May 20, 2026 |
| RLAY | PRESS-RELEASE | bearish | 7/10 | Relay Therapeutics priced a $275M underwritten public offering of 22.9M shares at $12.00/share, representing approximate | May 20, 2026 |
| LQDA | CLUSTER | neutral | 4/10 | CEO Roger Jeffs and director Bloch Stephen sold a combined ~$11M in LQDA shares over the past week, representing 0.21% o | May 20, 2026 |
| NBTX | PRESS-RELEASE | bearish | 5/10 | Nanobiotix launched a ~€75M (~$87M) global follow-on offering of ADSs and ordinary shares, plus pre-funded warrants. The | May 20, 2026 |
| HOWL | CLUSTER | neutral | 4/10 | Director Luke Evnin and 10% owner RA Capital Management sold a combined $72K in HOWL stock over a 7-day window, represen | May 20, 2026 |
| MEHA | 3 | neutral | 2/10 | David R. Wells filed a Form 3 initial statement of beneficial ownership after becoming Chief Financial Officer of Functi | May 20, 2026 |
| PHVS | CLUSTER | neutral | 3/10 | Four insiders at Pharvaris, including the CEO and Chief Commercial Officer, sold shares totaling $786K in open-market tr | May 20, 2026 |
| DYN | PRESS-RELEASE | neutral | 2/10 | Dyne Therapeutics granted inducement equity awards to 17 newly hired employees, consisting of stock options for 296,500 | May 20, 2026 |
| PCRX | DEFA14A | mixed | 6/10 | Pacira BioSciences filed additional definitive proxy soliciting materials (DEFA14A) urging stockholders to vote FOR mana | May 20, 2026 |